How pharmacokinetic/pharmacodynamic models can inform the development of new HIV medications.

There remains a need for new HIV medications. This has been challenged by the increasing costs associated with drug discovery and testing. One solution to this issue involves the incorporation of pharmacokinetic/pharmacodynamic (PK/PD) models into the development pipeline. This article provides an overview of how PK/PD models can be used to provide insights to aid this endeavour. This article is part of the Theo Murphy meeting issue 'Evaluating anti-infective drugs'.